Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 42

Phase 2 UTI Programs Underway Adaptive Dosing Designs Employed in Cystitis and Acute Pyelonephritis Studies ~200 patients oral omadacycline (up to 450mg) 7 days oral nitrofurantoin 7 days Day 14 (+/- 2d) Post-Therapy Evaluation (PTE) Day 1 Day 7 End of Treatment (EOT) Day 30 - 37 Final Follow-up Cystitis IV omadacycline 7-10 days IV to oral levofloxacin 7-10 days Days 21 (± 2 days) PTE Day 1 Day 7-10 EOT Day 28 (± 2 days) Final Follow-up IV to oral omadacycline 7-10 days Acute Pyelonephritis (1) Design and comparator subject to FDA discussions prior to initiation